Patritumab

Research use only, not for human use.

Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer.

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.

Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis.Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells.Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression.:Western Blot Analysis Cell Line:DiFi-HRG cells Concentration:10 μg/mL Incubation Time:6 hours Result:Inhibited the phosphorylation of HER3 and AKT as well as down-regulated survivin expression.

Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice.Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo.Animal Model:Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)Dosage:1 mg/body Administration:Intraperitoneal injection; twice a week for 4 weeks Result:Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line.Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.

——

MAPK/ERK Signaling

ERK

ERK | EGFR | HER | Akt

——

——

1262787-83-6

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years